Applications and simulations of a discontinuous oral absorption pharmacokinetic model
- PMID: 8956341
- DOI: 10.1023/a:1016457110726
Applications and simulations of a discontinuous oral absorption pharmacokinetic model
Abstract
Purpose: To illustrate the application of a discontinuous oral absorption model to cimetidine and ranitidine plasma concentration versus time data to demonstrate the use of the model for drugs which display discontinuous oral absorption profiles, and to illustrate the effect of various model parameters on plasma drug concentration versus time profiles and bioavailability.
Methods: A discontinuous oral absorption model was used to fit ranitidine and cimetidine serum concentrations following oral and intravenous administration. The model was also used to simulate bioavailability and plasma concentrations versus time profiles for various parameter values.
Results: Serum concentrations following administration of ranitidine and cimetidine were well described by the model, and parameter estimates obtained were in agreement with literature values. Simulations demonstrate the effects of various absorption parameters and gastroin-testinal tract transit parameters on bioavailability and plasma concentration profiles.
Conclusions: This discontinuous oral absorption pharmacokinetic model can be a useful tool in characterizing absorption phases, disposition, and bioavailability of drugs exhibiting two absorption peaks following oral administration.
Similar articles
-
Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.Pharm Res. 1992 Mar;9(3):350-6. doi: 10.1023/a:1015890918883. Pharm Res. 1992. PMID: 1614968
-
Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses.J Vet Pharmacol Ther. 2017 Jan;40(1):92-96. doi: 10.1111/jvp.12328. Epub 2016 Jun 13. J Vet Pharmacol Ther. 2017. PMID: 27292271
-
A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption.Med Eng Phys. 1999 Oct;21(8):525-32. doi: 10.1016/s1350-4533(99)00060-0. Med Eng Phys. 1999. PMID: 10672785
-
Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine.J Clin Gastroenterol. 1983;5 Suppl 1:81-90. doi: 10.1097/00004836-198312001-00008. J Clin Gastroenterol. 1983. PMID: 6317740 Review.
-
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.Clin Pharmacokinet. 1996 Nov;31(5):386-406. doi: 10.2165/00003088-199631050-00005. Clin Pharmacokinet. 1996. PMID: 9118586 Review.
Cited by
-
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.Clin Pharmacokinet. 2006;45(4):385-99. doi: 10.2165/00003088-200645040-00004. Clin Pharmacokinet. 2006. PMID: 16584285 Clinical Trial.
-
A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.Clin Pharmacokinet. 2003;42(2):179-92. doi: 10.2165/00003088-200342020-00005. Clin Pharmacokinet. 2003. PMID: 12537516 Clinical Trial.
-
Multiple peaking phenomena in pharmacokinetic disposition.Clin Pharmacokinet. 2010 Jun;49(6):351-77. doi: 10.2165/11319320-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20481648 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources